Bipolar I and II disorder residual symptoms: Oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 1, 2009, Pages 94-99

  Juruena, M F ^a,b,c   Ottoni, G L ^b   Machado Vieira, R ^b,d   Carneiro, R M ^b   Weingarthner, N ^b   Marquardt, A R ^b   Fleig, S S ^b   Broilo, L ^b   Busnello, E A ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c BETHLEM ROYAL HOSPITAL   (United Kingdom)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bipolar disorder; Carbamazepine; Clinical trial; Lithium; Oxcarbazepine; Residual symptoms

Indexed keywords

CARBAMAZEPINE; LITHIUM; OXCARBAZEPINE;

ADULT; ARTICLE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HUMAN; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; TREMOR; VOMITING; WEIGHT GAIN; XEROSTOMIA; YOUNG MANIA RATING SCALE;

ADULT; ANTIMANIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; DEPRESSION; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 58249083993     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.10.012     Document Type: Article

References (31)

1. Angst J., and Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry 48 (2000) 445-457
2. Angst J., Felder W., and Lohmeyer B. Course of schizoaffective psychoses: results of a followup study. Fortschr Neurol Psychiatr 48 (1980) 3-30
3. Ballenger J.C. The clinical use of carbamazepine in affective disorders. J Clin Psychiatry 49 Suppl (1988) 13-21 Apr
4. Bauwens F., Pardoen D., Staner L., Dramaix M., and Mendlewicz J. Social adjustment and the course of affective illness; a 1-year controlled longitudinal study involving bipolar and unipolar outpatients. Depress Anxiety 8 (1998) 50-57
5. Benedetti A., Lattanzi L., Pini S., Musetti L., Dell'Osso L., and Cassano G.B. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. J Affect Disord 79 1-3 (2004) 273-277 Apr
6. Bowden C.L. Role of newer medications for bipolar disorder. J Clin Psychopharmacol 16 2 Suppl 1 (1996) 48S-55S
7. Cabrera J., Albrecht J., and Müller-Oerlinghausen B. Combined preventive treatment of recurrent manic-depressive disease with lithium and carbamazepine or oxcarbazepine. Nervenarzt 58 4 (1987) 245-249 Apr
8. Ceylan M.E., and Oral E.T. Biological psychiatry in research and clinical application: Mood Disorders (2001), İstanbul, Altan Matbaacilik
9. Emrich H.M. Studies with oxcarbazepine (trileptal) in acute mania. Int Clin Psychopharmacol 5 (1990) 83-88
10. Emrich H.M., Altmann H., Dose M., and Von Zerssen D. Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report. Pharmacol Biochem Behav 19 (1983) 369-372
11. Emrich H.M., Dose M., and Von Zerssen D. Action of sodium-valproate and of oxcarbazepine in patients with affective disorder. In: Emrich H.M., Okuma T., and Mueller A.A. (Eds). Anticonvulsants in affective disorders (1984), Elsevier Science Publishers BV, Amsterdam
12. Emrich H.M., Dose M., and von Zersson D. The use of sodium valproate, carbamazepine and oxcarbazepine in patients with affective disorders. J Affect Disord 8 (1985) 243-250
13. Endicott J., and Spitzer R.L. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35 (1978) 837-844 Jul
14. Frye M.A., Ketter T.A., Leverich G.S., Huggins T., Lantz C., Denicoff D.K., et al. The increasing use of polypharmacology for refractory mood disorders: 22 years of study. J Clin Psychiatry 61 (2000) 9-15
15. Goodwin G.M. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17 2 (2003) 149-173
16. Hirschfeld R.M., and Kasper S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol 7 4 (2004) 507-522 Dec
17. Mueller A.A., and Stoll K.D. Carbamazepine and oxcarbamazepine in the treatment of manic syndromes: studies in Germany. In: Emrich H.M., Okuma T., and Muller A.A. (Eds). Anticonvulsants in affective disorders. Int. Congr. Ser. vol. 626 (1984), Excerpta Medica, Amsterdam, The Netherlands 139-147
18. Munoz A. Oxcarbazepine for the treatment of bipolar disorder, poster presentation (2002), American Psychiatric Association, Philadelphia
19. NICE guidelines: Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care guidance type: clinical guideline. www.nice.org.uk/CG38, 2006.
20. Okuma T., Yamashjta I., Takahashi R., Itoh H., Otsuki S., Watanabe S., et al. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 23 (1990) 143-150
21. Post R.M., Uhde T.W., Roy-Byrne P.P., and Joffe R.T. Antidepressant effects of carbamazepine. Am J Psychiatry 43 1 (1986) 29-34 Jan, 1
22. Rybakowski J.K., Suwalska A., and Chlopocka-Woźniak M. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 40 3 (1999) 134-139 Sep
23. Small J.G., Klapper M.H., Milstein V., Kellams J.J., Miller M.J., Marhenke J.D., et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 48 10 (1991) 915-921 Oct
24. Smith L.A., Cornelius V., Warnock A., Tacchi M.J., and Taylor D. Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials. Bipolar Disord 9 6 (2007) 551-560
25. Soares-Weiser K., Bravo Vergel Y., Beynon S., Dunn G., Barbieri M., Duffy S., et al. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. Health Technol Assess 11 39 (2007) Oct, ii-iv, ix-206
26. Spitzer R.L., Endicott J., and Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 35 (1978) 773-782
27. Statistical Package for the Social Sciences for Windows. Statistical package for the social sciences for windows, release 15.0 (2006), Copyright SPSS Inc, Chicago, IL
28. Vasudev A., Macritchie K., Watson S., Geddes J.R., and Young A.H. Oxcarbazepine in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 1 CD005171 (2008) Jan 23
29. Vieta E., Cruz N., Garcia-Campayo J., de Arce R., Crespo J.M., Valle`s V., et al. A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 11 4 (2008) 445-452 Jun
30. Wildgrube C. Case studies on prophylactic long-term effects of oxcarbazepine in recurrent affective disorders. Int Clin Psychopharmacol 5 (1990) 89S-94S
31. Yatham L.N., Kennedy S.H., O'Donovan C., Parikh S.V., MacQueen G., McIntyre R.S., et al. Canadian network for mood and anxiety treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 8 6 (2006) 721-739